(GRF) Grifols S.A. - Overview
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: MC (Spain) | Market Cap: 6.444m EUR | Total Return: 2.7% in 12m
Avg Turnover: 18.1M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Grifols S.A. is a Spanish healthcare company specializing in the development and production of plasma-derived medicines and diagnostic systems. The firm operates an integrated business model that spans the collection of human plasma through its own centers to the manufacturing of specialized proteins used in treating immunology, hematology, and neurology disorders. Its operations are divided into four primary segments: Biopharma, Diagnostic, Bio Supplies, and Others.
The plasma industry is characterized by high barriers to entry due to the complex regulatory requirements for collection facilities and the capital-intensive nature of fractionation plants. Beyond its core plasma business, Grifols provides hospital pharmacy automation technology and intravenous solutions to healthcare providers globally. To understand the underlying valuation metrics of this business, you may wish to review the detailed financial breakdowns on ValueRay.
Headquartered in Barcelona, the company maintains a significant global footprint with a primary focus on the North American and European markets. Its product portfolio includes essential biological products such as albumin and immunoglobulins, which are critical for intensive care and chronic disease management.
- Global plasma collection volumes and costs directly impact Biopharma segment profit margins
- High net debt levels and leverage ratios influence investor confidence and valuation
- Regulatory approval of new subcutaneous immunoglobulin treatments drives future revenue growth
- Strategic asset divestments and restructuring efforts aim to reduce corporate balance sheet risk
- Plasma-derived medicine demand in the United States remains the primary earnings catalyst
| Net Income: 415.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.72 > 1.0 |
| NWC/Revenue: 42.08% < 20% (prev 47.06%; Δ -4.99% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.02b > Net Income 415.2m |
| Net Debt (10.0b) to EBITDA (1.71b): 5.89 < 3 |
| Current Ratio: 2.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (680.6m) vs 12m ago 0.02% < -2% |
| Gross Margin: 37.68% > 18% (prev 0.39%; Δ 3.73k% > 0.5%) |
| Asset Turnover: 36.23% > 50% (prev 35.14%; Δ 1.09% > 0%) |
| Interest Coverage Ratio: 2.04 > 6 (EBITDA TTM 1.71b / Interest Expense TTM 614.6m) |
| A: 0.16 (Total Current Assets 5.25b - Total Current Liabilities 2.12b) / Total Assets 20.1b |
| B: 0.00 (Retained Earnings 73.0m / Total Assets 20.1b) |
| C: 0.06 (EBIT TTM 1.26b / Avg Total Assets 20.5b) |
| D: 0.39 (Book Value of Equity 4.75b / Total Liabilities 12.2b) |
| Altman-Z'' = 1.85 = BBB |
| DSRI: 0.91 (Receivables 958.0m/1.04b, Revenue 7.44b/7.37b) |
| GMI: 1.05 (GM 37.68% / 39.39%) |
| AQI: 1.01 (AQ_t 0.58 / AQ_t-1 0.58) |
| SGI: 1.01 (Revenue 7.44b / 7.37b) |
| TATA: -0.03 (NI 415.2m - CFO 1.02b) / TA 20.1b) |
| Beneish M = -3.08 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at EUR 9.50 with a total of 1,679,856 shares traded.
Over the past week, the price has changed by +4.14%,
over one month by +5.79%,
over three months by -13.93% and
over the past year by +2.70%.
Grifols S.A. has no consensus analysts rating.
P/E Trailing = 15.5213
P/E Forward = 12.5
P/S = 0.8663
P/B = 1.1843
P/EG = 0.283
Revenue TTM = 7.44b EUR
EBIT TTM = 1.26b EUR
EBITDA TTM = 1.71b EUR
Long Term Debt = 8.07b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 589.0m EUR (from shortTermDebt, last quarter)
Debt = 10.8b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.08b
Net Debt = 10.0b EUR (calculated: Debt 10.8b - CCE 702.0m)
Enterprise Value = 16.5b EUR (6.44b + Debt 10.8b - CCE 702.0m)
Interest Coverage Ratio = 2.04 (Ebit TTM 1.26b / Interest Expense TTM 614.6m)
EV/FCF = 21.88x (Enterprise Value 16.5b / FCF TTM 753.7m)
FCF Yield = 4.57% (FCF TTM 753.7m / Enterprise Value 16.5b)
FCF Margin = 10.13% (FCF TTM 753.7m / Revenue TTM 7.44b)
Net Margin = 5.58% (Net Income TTM 415.2m / Revenue TTM 7.44b)
Gross Margin = 37.68% ((Revenue TTM 7.44b - Cost of Revenue TTM 4.64b) / Revenue TTM)
Gross Margin QoQ = 36.47% (prev 34.68%)
Tobins Q-Ratio = 0.82 (Enterprise Value 16.5b / Total Assets 20.1b)
Interest Expense / Debt = 5.72% (Interest Expense 614.6m / Debt 10.8b)
Taxrate = 21.43% (24.0m / 112.0m)
NOPAT = 987.2m (EBIT 1.26b * (1 - 21.43%))
Current Ratio = 2.47 (Total Current Assets 5.25b / Total Current Liabilities 2.12b)
Debt / Equity = 1.97 (Debt 10.8b / totalStockholderEquity, last quarter 5.46b)
Debt / EBITDA = 5.89 (Net Debt 10.0b / EBITDA 1.71b)
Debt / FCF = 13.33 (Net Debt 10.0b / FCF TTM 753.7m)
Total Stockholder Equity = 5.27b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.02% (Net Income 415.2m / Total Assets 20.1b)
RoE = 7.88% (Net Income TTM 415.2m / Total Stockholder Equity 5.27b)
RoCE = 9.42% (EBIT 1.26b / Capital Employed (Equity 5.27b + L.T.Debt 8.07b))
RoIC = 5.32% (NOPAT 987.2m / Invested Capital 18.5b)
WACC = 5.60% (E(6.44b)/V(17.2b) * Re(7.44%) + D(10.8b)/V(17.2b) * Rd(5.72%) * (1-Tc(0.21)))
Discount Rate = 7.44% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 17.98 | Cagr: 0.10%
[DCF] Terminal Value 73.10% ; FCFF base≈827.6m ; Y1≈725.8m ; Y5≈586.4m
[DCF] Fair Price = N/A (negative equity: EV 9.41b - Net Debt 10.0b = -636.6m; debt exceeds intrinsic value)
EPS Correlation: 94.40 | EPS CAGR: 54.55% | SUE: -0.48 | # QB: 0
Revenue Correlation: 96.50 | Revenue CAGR: 6.66% | SUE: -0.73 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.24 | Chg30d=N/A | Revisions=+20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.25 | Chg30d=N/A | Revisions=-20% | Analysts=1
EPS current Year (2026-12-31): EPS=0.87 | Chg30d=-5.87% | Revisions=-43% | GrowthEPS=+18.8% | GrowthRev=+2.2%
EPS next Year (2027-12-31): EPS=1.14 | Chg30d=-4.56% | Revisions=-56% | GrowthEPS=+30.8% | GrowthRev=+6.7%
[Analyst] Revisions Ratio: -56%